Defining daptomycin resistance prevention exposures in vancomycin-resistant Enterococcus faecium and E. faecalis

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 9, 2014, Pages 5253-5261

  Werth, B J ^a,i   Steed, M E ^c   Ireland, C E ^a   Tran, T T ^d   Nonejuie, P ^h   Murray, B E ^d   Rose, W E ^f   Sakoulas, G ^g   Pogliano, J ^h   Arias, C A ^d,e   Rybak, M J ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KANSAS   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e UNIVERSIDAD EL BOSQUE   (Colombia)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLIPIN; CYCLOPROPANE; DAPTOMYCIN; FATTY ACID SYNTHASE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; CELL MEMBRANE DEPOLARIZATION; DRUG EXPOSURE; DRUG HALF LIFE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GENE MUTATION; GROWTH RATE; HOMEOSTASIS; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; SURFACE CHARGE; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; VANCOMYCIN RESISTANCE;

EID: 84906096917     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00098-14     Document Type: Article

References (34)

1. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S, National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities. 2013. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect. Control Hosp. Epidemiol. 34:1-14. http://dx.doi.org/10.1086/668770.
2. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12. http://dx.doi.org/10.1086/595011.
3. Arias CA, Contreras GA, Murray BE. 2010. Management of multidrug-resistant enterococcal infections. Clin. Microbiol. Infect. 16:555-562. http://dx.doi.org/10.1111/j.1469-0691.2010.03214.x.
4. Rivera AM, Boucher HW. 2011. Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci. Mayo Clin. Proc. 86:1230-1243. http://dx.doi.org/10.4065/mcp.2011.0514.
5. Cha R, Rybak MJ. 2003. Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Diagn. Microbiol. Infect. Dis. 47:539-546. http://dx.doi.org/10.1016/S0732-8893(03)00119-6. (Pubitemid 37338519)
6. Sader HS, Watters AA, Fritsche TR, Jones RN. 2007. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005). BMC Infect. Dis. 7:29. http://dx.doi.org/10.1186/1471-2334-7-29.
7. Munoz-Price LS, Lolans K, Quinn JP. 2005. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. Clin. Infect. Dis. 41:565-566. http://dx.doi.org/10.1086/432121. (Pubitemid 41099656)
8. Lewis JS, Jr., Owens A, Cadena J, Sabol K, Patterson JE, Jorgensen JH. 2005. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob. Agents Chemother. 49:1664-1665. http://dx.doi.org/10.1128/AAC.49.4.1664-1665.2005. (Pubitemid 40463418)
9. Green MR, Anasetti C, Sandin RL, Rolfe NE, Greene JN. 2006. Development of daptomycin resistance in a bone marrow transplant patient with vancomycin-resistant Enterococcus durans. J. Oncol. Pharm. Pract. 12:179-181. http://dx.doi.org/10.1177/1078155206069165. (Pubitemid 44696445)
10. Kamboj M, Cohen N, Gilhuley K, Babady NE, Seo SK, Sepkowitz KA. 2011. Emergence of daptomycin-resistant VRE: experience of a single institution. Infect. Control Hosp. Epidemiol. 32:391-394. http://dx.doi.org/10.1086/659152.
11. Arias CA, Panesso D, McGrath DM, Qin X, Mojica MF, Miller C, Diaz L, Tran TT, Rincon S, Barbu EM, Reyes J, Roh JH, Lobos E, Sodergren E, Pasqualini R, Arap W, Quinn JP, Shamoo Y, Murray BE, Weinstock GM. 2011. Genetic basis for in vivo daptomycin resistance in enterococci. N. Engl. J. Med. 365: 892-900. http://dx.doi.org/10.1056/NEJMoa1011138.
12. Tran TT, Panesso D, Gao H, Roh JH, Munita JM, Reyes J, Diaz L, Lobos EA, Shamoo Y, Mishra NN, Bayer AS, Murray BE, Weinstock GM, Arias CA. 2013. Whole-genome analysis of a daptomycin-susceptible Enterococcus faecium strain and its daptomycin-resistant variant arising during therapy. Antimicrob. Agents Chemother. 57:261-268. http://dx.doi.org/10.1128/AAC.01454-12.
13. Lamp KC, Rybak MJ. 1993. Teicoplanin and daptomycin bactericidal activities in the presence of albumin or serum under controlled conditions of pH and ionized calcium. Antimicrob. Agents Chemother. 37:605-609. http://dx.doi.org/10.1128/AAC.37.3.605. (Pubitemid 23072611)
14. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement, vol 32. Clinical and Laboratory Standards Institute, Wayne, PA.
15. Hershberger E, Coyle EA, Kaatz GW, Zervos MJ, Rybak MJ. 2000. Comparison of a rabbit model of bacterial endocarditis and an in vitro infection model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 44:1921-1924. http://dx.doi.org/10.1128/AAC.44.7.1921-1924.2000. (Pubitemid 30422949)
16. Dvorchik B, Damphousse D. 2004. Single-dose pharmacokinetics of daptomycin in young and geriatric volunteers. J. Clin. Pharmacol. 44:612-620. http://dx.doi.org/10.1177/0091270004265646. (Pubitemid 38668024)
17. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. 2006. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob. Agents Chemother. 50:3245-3249. http://dx.doi.org/10.1128/AAC.00247-06. (Pubitemid 44527494)
18. Steed ME, Werth BJ, Ireland CE, Rybak MJ. 2012. Evaluation of the novel combination of high-dose daptomycin plus trimethoprimsulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. Antimicrob. Agents Chemother. 56:5709-5714. http://dx.doi.org/10. 1128/AAC.01185-12.
19. Straus SK, Hancock RE. 2006. Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim. Biophys. Acta 1758:1215-1223. http://dx.doi.org/10.1016/j.bbamem.2006.02.009. (Pubitemid 44436068)
20. Kraus D, Herbert S, Kristian SA, Khosravi A, Nizet V, Gotz F, Peschel A. 2008. The GraRS regulatory system controls Staphylococcus aureus susceptibility to antimicrobial host defenses. BMC Microbiol. 8:85. http://dx.doi.org/10.1186/ 1471-2180-8-85.
21. Pogliano J, Osborne N, Sharp MD, Abanes-De Mello A, Perez A, Sun YL, Pogliano K. 1999. A vital stain for studying membrane dynamics in bacteria: a novel mechanism controlling septation during Bacillus subtilis sporulation. Mol. Microbiol. 31:1149-1159. http://dx.doi.org/10.1046/j.1365-2958.1999.01255.x. (Pubitemid 29082244)
22. Silverman JA, Perlmutter NG, Shapiro HM. 2003. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 47:2538-2544. http://dx.doi.org/10.1128/AAC.47.8. 2538-2544.2003. (Pubitemid 36919456)
23. Cui L, Ma X, Sato K, Okuma K, Tenover FC, Mamizuka EM, Gemmell CG, Kim MN, Ploy MC, El-Solh N, Ferraz V, Hiramatsu K. 2003. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J. Clin. Microbiol. 41:5-14. http://dx.doi.org/10.1128/JCM.41.1.5-14.2003. (Pubitemid 36098547)
24. Tran TT, Panesso D, Mishra NN, Mileykovskaya E, Guan Z, Munita JM, Reyes J, Diaz L, Weinstock GM, Murray BE, Shamoo Y, Dowhan W, Bayer AS, Arias CA. 2013. Daptomycin-resistant Enterococcus faecalis diverts the antibiotic molecule from the division septum and remodels cell membrane phospholipids. mBio 4(4):e00281-13. http://dx.doi.org/10.1128/mBio.00281-13.
25. Palmer KL, Daniel A, Hardy C, Silverman J, Gilmore MS. 2011. Genetic basis for daptomycin resistance in enterococci. Antimicrob. Agents Chemother. 55:3345-3356. http://dx.doi.org/10.1128/AAC.00207-11.
26. Paulsen IT, Banerjei L, Myers GS, Nelson KE, Seshadri R, Read TD, Fouts DE, Eisen JA, Gill SR, Heidelberg JF, Tettelin H, Dodson RJ, Umayam L, Brinkac L, Beanan M, Daugherty S, DeBoy RT, Durkin S, Kolonay J, Madupu R, Nelson W, Vamathevan J, Tran B, Upton J, Hansen T, Shetty J, Khouri H, Utterback T, Radune D, Ketchum KA, Dougherty BA, Fraser CM. 2003. Role of mobile DNA in the evolution of vancomycin-resistant Enterococcus faecalis. Science 299:2071-2074. http://dx.doi.org/10.1126/science.1080613. (Pubitemid 36383734)
27. Qin X, Galloway-Pena JR, Sillanpaa J, Roh JH, Nallapareddy SR, Chowdhury S, Bourgogne A, Choudhury T, Muzny DM, Buhay CJ, Ding Y, Dugan-Rocha S, Liu W, Kovar C, Sodergren E, Highlander S, Petrosino JF, Worley KC, Gibbs RA, Weinstock GM, Murray BE. 2012. Complete genome sequence of Enterococcus faecium strain TX16 and comparative genomic analysis of Enterococcus faecium genomes. BMC Microbiol. 12:135. http://dx.doi.org/10.1186/1471-2180-12-135.
28. Wu G, Abraham T, Rapp J, Vastey F, Saad N, Balmir E. 2011. Daptomycin: evaluation of a high-dose treatment strategy. Int. J. Antimicrob. Agents 38:192-196. http://dx.doi.org/10.1016/j.ijantimicag.2011.03.006.
29. Parra-Ruiz J, Pena-Monje A, Tomas-Jimenez C, Pomares-Mora J, Hernandez-Quero J. 2011. Efficacy and safety of high dose (≥8 mg/kg/day) daptomycin. Enferm. Infecc. Microbiol. Clin. 29:425-427. (In Spanish.) http://dx.doi.org/10.1016/j.eimc.2011.02.012.
30. Casapao AM, Kullar R, Davis SL, Levine DP, Zhao JJ, Potoski BA, Goff DA, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. 2013. Multicenter study of high-dose daptomycin for treatment of enterococcal infections. Antimicrob. Agents Chemother. 57:4190-4196. http://dx.doi.org/10.1128/AAC.00526-13.
31. Sader HS, Fritsche TR, Kaniga K, Ge Y, Jones RN. 2005. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob. Agents Chemother. 49:3501-3512. http://dx.doi.org/10.1128/AAC.49.8.3501-3512.2005. (Pubitemid 41060605)
32. Miro JM, Pericas JM, del Rio A, Hospital Clinic Endocarditis Study Group. 2013. A new era for treating Enterococcus faecalis endocarditis: ampicillin plus short-course gentamicin or ampicillin plus ceftriaxone: that is the question! Circulation 127:1763-1766. http://dx.doi.org/10.1161/CIRCULATIONAHA. 113.002431.
33. Miller C, Kong J, Tran TT, Arias CA, Saxer G, Shamoo Y. 2013. Adaptation of Enterococcus faecalis to daptomycin reveals an ordered progression to resistance. Antimicrob. Agents Chemother. 57:5373-5383. http://dx.doi.org/10. 1128/AAC.01473-13.
34. Humphries RM, Pollett S, Sakoulas G. 2013. A current perspective on daptomycin for the clinical microbiologist. Clin. Microbiol. Rev. 26:759-780. http://dx.doi.org/10.1128/CMR.00030-13.